Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2025
Subject: Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt balances, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On August 12, 2025, the Company entered into a Retention Letter Agreement with Mark Frost, Interim Chief Financial Officer. Key terms include:
- Retention Bonus: A cash bonus of $100,000 is payable upon successful refinancing of the Company's existing term loan and senior revolving credit facility prior to March 15, 2026.
- Conditions: Eligibility requires Mr. Frost's continued employment through the refinancing date or the Retention Date, unless terminated without cause.
- Replacement of Prior Offer: This bonus replaces a previously offered $50,000 cash bonus from an April 10, 2025 offer letter.
- Termination Benefits: In the event of termination without cause prior to the Retention Date, the Company must provide five months of base salary and COBRA premiums, subject to a general release of claims.
Guidance, Outlook, and Risks
Outlook: The filing indicates an active effort to refinance existing indebtedness (term loan and senior revolving credit facility) by March 15, 2026.
Risks: The retention bonus is contingent on the successful completion of this refinancing. Failure to refinance by the deadline would result in the forfeiture of the $100,000 bonus.
Investor Verification Checklist
- Verify the current status and terms of the Company's existing term loan and senior revolving credit facility.
- Monitor future filings for confirmation of the refinancing transaction or any changes to the debt structure.
- Review the full text of the Retention Letter Agreement (Exhibit 10.1) for specific definitions of "successful refinancing" and termination clauses.
- Assess the impact of the increased executive compensation liability ($100,000 vs. $50,000) on the Company's cash flow projections.